Drug Trial Radar · NCT07864584
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 11, 2027
Primary completion
Jul 13, 2029
Study completion Jul 12, 2030
Sponsor
- Lead sponsor
- Nob Hill Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are 3 parts to this clinical trial. The goal of this clinical trial (NHT102-001) is to learn how safe NHT102 is, what dose works best, and whether it can help treat advanced non-small cell lung cancer (NSCLC) that has come back or remained after earlier treatment and is still confined to the lung / chest region by providing targeted inhaled treatment directly to the lungs. NHT102 is a dry powder that participants breathe in through a mouthpiece using an investigational inhalation device. Doses are given at the study site by trained staff, not at home. NHT102 is taken on days 1-5 and days 15-19 of a 28-day cycle. The main questions this clinical trial aims to answer are: Part 1 (Dose Escalation): To look at up to five different increasing dose levels of NHT102 to see if they are safe and well-tolerated and if the body absorbs the medicine from the lungs. To see if up to two dose levels studied are not only safe, but also make the cancer slow its growth or lessen its spread. And to see the highest dose that is tolerated by participants. Part 2 (Dose Optimization): To further study at up to two dose levels from Part 1 and randomly assign participants in equal numbers to one of them to learn more about NHT102's safety, how well the drug is absorbed from the lungs and how well each dose level works against the NSCLC after at least 4 months. Then identify which of the two doses is chosen for further study. Part 3 (Dose Expansion): Take the dose chosen in from Part 2 and study it in more patients to continue look at the drug safety, how much of it is absorbed into the body from the lungs and if it works to stop or reduce the spread of NSCLC. Participants will: * Take NHT102 at the study site daily on days 1-5 days and days 15-19 during a 28-day cycle for as long as it is helping them and they can tolerate it. Treatment stops if the cancer worsens, if side effects become too difficult to manage, or if the participant or their doctor decides to stop. * Tell doctors and staff about all medications they are taking, any issues with their study medication and all side effects they may be having whether they are taking the medication that day or not. * Return for a safety visit about 30 days after their last dose, then receive phone calls about 3 months and 6 months later to check on their health.
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
NHT102Drug
NHT102 is an investigational drug product, 5-Azacytidine dry powder for oral inhalation. NHT102 is administered once daily via inhalation using a novel investigational inhalation delivery system. Dosing occurs on Days 1-5 and Days 15-19 of each 28-day cycle. Multiple dose levels (7 mg to 42 mg target lung dose per treatment day) are evaluated in Part 1, selected dose levels in Part 2, and the recommended Phase 2 dose (RP2D) in Part 3.
DryNebDevice
The DryNeb is a novel investigational inhalation delivery system that delivers micronized dry powder to the lungs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: From first dose through 30 days after the last dose.
- Incidence of dose-limiting toxicities (DLT)-Part ITime frame: 28-day DLT evaluation period (Cycle 1)
- Overall Response Rate (ORR)-Parts 2 and 3.Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.
- Progression Free Survival (PFS)-Parts 2 and 3.Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.
- Overall Survival (OS)-Parts 2 and 3.Time frame: From first dose until first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.
- Duration of Response (DOR)-Parts 2 and 3.Time frame: From first documented response to date of first documented disease progression, date of death or patient withdrawal from the study for any reason, assessed up to six months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gabrail Cancer Center Research
Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.